ACADIA Pharmaceuticals/$ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Ticker
$ACAD
Sector
Primary listing
Employees
654
Headquarters
Website
ACAD Metrics
BasicAdvanced
$4.2B
18.61
$1.33
0.71
-
Price and volume
Market cap
$4.2B
Beta
0.71
52-week high
$26.65
52-week low
$13.40
Average daily volume
2M
Financial strength
Current ratio
2.911
Quick ratio
2.672
Long term debt to equity
5.423
Total debt to equity
5.423
Profitability
EBITDA (TTM)
103.965
Gross margin (TTM)
60.22%
Net profit margin (TTM)
21.80%
Operating margin (TTM)
8.86%
Effective tax rate (TTM)
17.07%
Revenue per employee (TTM)
$1,560,000
Management effectiveness
Return on assets (TTM)
5.28%
Return on equity (TTM)
33.18%
Valuation
Price to earnings (TTM)
18.609
Price to revenue (TTM)
4.038
Price to book
5.06
Price to tangible book (TTM)
5.87
Price to free cash flow (TTM)
46.627
Free cash flow yield (TTM)
2.14%
Free cash flow per share (TTM)
0.529
Growth
Revenue change (TTM)
14.41%
Earnings per share change (TTM)
615.00%
3-year revenue growth (CAGR)
25.75%
10-year revenue growth (CAGR)
161.94%
3-year earnings per share growth (CAGR)
1.44%
10-year earnings per share growth (CAGR)
-0.09%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
Bulls say / Bears say
Second quarter 2025 total revenues rose 9% year-over-year to $264.6 million, driven by a 7% increase in NUPLAZID and 14% growth in DAYBUE sales, and the company raised the low end of Nuplazid guidance for 2025 (Business Wire)
The U.S. Court of Appeals upheld Acadia’s composition-of-matter and formulation patents for pimavanserin, securing exclusivity for Nuplazid through 2030 and its capsule formulation until 2038, strengthening long-term revenue protection (Reuters)
Acadia hosted its inaugural R&D Day in June 2025, showcasing nine disclosed programs and detailing plans for seven Phase 2 or Phase 3 studies to initiate during 2025–2026, underscoring the depth and potential of its CNS and rare disease pipeline (Business Wire)
ACAD trades at approximately 87.97x forward P/E and 2.97x price-to-sales, materially above the biotechnology sector norms, indicating a stretched valuation that could limit upside if growth slows (Reuters)
Selling, general and administrative expenses jumped 14% year-over-year to $133.5 million in Q2 2025, outpacing revenue growth and exerting pressure on operating margins (Business Wire)
Key pipeline catalyst—top-line results for the Phase 3 COMPASS PWS study of ACP-101—are not expected until early Q4 2025, leaving the stock exposed to volatility in the absence of near-term positive news (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Business Wire4 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 week ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $4.2B as of September 16, 2025.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 18.61 as of September 16, 2025.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.